Compare FTCI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | CUE |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 124.5M |
| IPO Year | 2021 | 2017 |
| Metric | FTCI | CUE |
|---|---|---|
| Price | $3.85 | $31.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $10.80 | ★ $120.00 |
| AVG Volume (30 Days) | 106.5K | ★ 115.0K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,687,000.00 | $27,466,000.00 |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $45.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 110.51 | ★ 195.75 |
| 52 Week Low | $3.21 | $0.17 |
| 52 Week High | $12.75 | $45.50 |
| Indicator | FTCI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 32.71 | 53.29 |
| Support Level | $3.30 | $23.88 |
| Resistance Level | $5.40 | $32.82 |
| Average True Range (ATR) | 0.41 | 4.68 |
| MACD | -0.12 | -0.52 |
| Stochastic Oscillator | 6.70 | 26.82 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.